These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22269110)

  • 1. Discovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptase.
    Ekkati AR; Bollini M; Domaoal RA; Spasov KA; Anderson KS; Jorgensen WL
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1565-8. PubMed ID: 22269110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase--structure-activity relationships and crystallographic analysis.
    Kirschberg TA; Balakrishnan M; Huang W; Hluhanich R; Kutty N; Liclican AC; McColl DJ; Squires NH; Lansdon EB
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1131-4. PubMed ID: 18083512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and anti-HIV activity of some heterodimers [NRTI]-glycyl-succinyl-[trovirdine analogue] of known HIV-1 reverse transcriptase inhibitors.
    Sugeac E; Fossey C; Ladurée D; Schmidt S; Laumond G; Aubertin AM
    J Enzyme Inhib Med Chem; 2003 Apr; 18(2):175-86. PubMed ID: 12943202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms.
    Li D; Zhan P; De Clercq E; Liu X
    J Med Chem; 2012 Apr; 55(8):3595-613. PubMed ID: 22268494
    [No Abstract]   [Full Text] [Related]  

  • 5. Discovery and crystallography of bicyclic arylaminoazines as potent inhibitors of HIV-1 reverse transcriptase.
    Lee WG; Frey KM; Gallardo-Macias R; Spasov KA; Chan AH; Anderson KS; Jorgensen WL
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4824-4827. PubMed ID: 26166629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
    Chan JH; Freeman GA; Tidwell JH; Romines KR; Schaller LT; Cowan JR; Gonzales SS; Lowell GS; Andrews CW; Reynolds DJ; St Clair M; Hazen RJ; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Koszalka GW; Boone LR
    J Med Chem; 2004 Feb; 47(5):1175-82. PubMed ID: 14971897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, discovery, modelling, synthesis, and biological evaluation of novel and small, low toxicity s-triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Viira B; Selyutina A; García-Sosa AT; Karonen M; Sinkkonen J; Merits A; Maran U
    Bioorg Med Chem; 2016 Jun; 24(11):2519-2529. PubMed ID: 27108399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of the Aryl-phospho-indole IDX899, a Highly Potent Anti-HIV Non-nucleoside Reverse Transcriptase Inhibitor.
    Dousson C; Alexandre FR; Amador A; Bonaric S; Bot S; Caillet C; Convard T; da Costa D; Lioure MP; Roland A; Rosinovsky E; Maldonado S; Parsy C; Trochet C; Storer R; Stewart A; Wang J; Mayes BA; Musiu C; Poddesu B; Vargiu L; Liuzzi M; Moussa A; Jakubik J; Hubbard L; Seifer M; Standring D
    J Med Chem; 2016 Mar; 59(5):1891-8. PubMed ID: 26804933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of nonnucleoside HIV reverse transcriptase inhibitors.
    Tucker TJ; Lumma WC; Culberson JC
    Methods Enzymol; 1996; 275():440-72. PubMed ID: 9026654
    [No Abstract]   [Full Text] [Related]  

  • 10. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
    Freeman GA; Andrews Iii CW; Hopkins AL; Lowell GS; Schaller LT; Cowan JR; Gonzales SS; Koszalka GW; Hazen RJ; Boone LR; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Reynolds DJ; Milton J; Ren J; Stuart DI; Stammers DK; Chan JH
    J Med Chem; 2004 Nov; 47(24):5923-36. PubMed ID: 15537347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
    Jin X; Piao HR; Pannecouque C; De Clercq E; Zhuang C; Chen FE
    Eur J Med Chem; 2021 Dec; 226():113868. PubMed ID: 34583311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motif.
    Li W; Li X; De Clercq E; Zhan P; Liu X
    Eur J Med Chem; 2015 Sep; 102():167-79. PubMed ID: 26276432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
    Sweeney ZK; Harris SF; Arora SF; Javanbakht H; Li Y; Fretland J; Davidson JP; Billedeau JR; Gleason SK; Hirschfeld D; Kennedy-Smith JJ; Mirzadegan T; Roetz R; Smith M; Sperry S; Suh JM; Wu J; Tsing S; Villaseñor AG; Paul A; Su G; Heilek G; Hang JQ; Zhou AS; Jernelius JA; Zhang FJ; Klumpp K
    J Med Chem; 2008 Dec; 51(23):7449-58. PubMed ID: 19007201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-2-aryl O-substituted HI-236 derivatives as non-nucleoside HIV-1 reverse-transcriptase inhibitors.
    Hunter R; Younis Y; Muhanji CI; Curtin TL; Naidoo KJ; Petersen M; Bailey CM; Basavapathruni A; Anderson KS
    Bioorg Med Chem; 2008 Dec; 16(24):10270-80. PubMed ID: 18996020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Wan ZY; Yao J; Tao Y; Mao TQ; Wang XL; Lu YP; Wang HF; Yin H; Wu Y; Chen FE; De Clercq E; Daelemans D; Pannecouque C
    Eur J Med Chem; 2015 Jun; 97():1-9. PubMed ID: 25935383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
    Wu B; Kuhen K; Ngoc Nguyen T; Ellis D; Anaclerio B; He X; Yang K; Karanewsky D; Yin H; Wolff K; Bieza K; Caldwell J; He Y
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3430-3. PubMed ID: 16632349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.
    Côté B; Burch JD; Asante-Appiah E; Bayly C; Bédard L; Blouin M; Campeau LC; Cauchon E; Chan M; Chefson A; Coulombe N; Cromlish W; Debnath S; Deschênes D; Dupont-Gaudet K; Falgueyret JP; Forget R; Gagné S; Gauvreau D; Girardin M; Guiral S; Langlois E; Li CS; Nguyen N; Papp R; Plamondon S; Roy A; Roy S; Seliniotakis R; St-Onge M; Ouellet S; Tawa P; Truchon JF; Vacca J; Wrona M; Yan Y; Ducharme Y
    Bioorg Med Chem Lett; 2014 Feb; 24(3):917-22. PubMed ID: 24412110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
    Meng Q; Chen X; Kang D; Huang B; Li W; Zhan P; Daelemans D; De Clercq E; Pannecouque C; Liu X
    Eur J Med Chem; 2016 Jun; 115():53-62. PubMed ID: 26994843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
    Hopkins AL; Ren J; Milton J; Hazen RJ; Chan JH; Stuart DI; Stammers DK
    J Med Chem; 2004 Nov; 47(24):5912-22. PubMed ID: 15537346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diaryl ethers with carboxymethoxyphenacyl motif as potent HIV-1 reverse transcriptase inhibitors with improved solubility.
    Frączek T; Kamiński R; Krakowiak A; Naessens E; Verhasselt B; Paneth P
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):9-16. PubMed ID: 29098886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.